Skip to main content

ADVERTISEMENT

skeletal-related events

Research in Review
01/30/2017
JCP Editors
A less-frequent dosing schedule of a bone-modifying agent (BMA) for treatment of skeletal-related events related to metastatic breast cancer is noninferior to standard dosing, according to research published in JAMA...
A less-frequent dosing schedule of a bone-modifying agent (BMA) for treatment of skeletal-related events related to metastatic breast cancer is noninferior to standard dosing, according to research published in JAMA...
A...
01/30/2017
Journal of Clinical Pathways